Viromed Medical AG Announces Plan to Acquire pharmedix GmbH

Viromed Medical AG is set to acquire all shares of pharmedix GmbH through a capital increase against a contribution in kind, without involving subscription rights. The agreement, announced on December 3, 2024, aims to expand Viromed's portfolio significantly.

pharmedix GmbH, founded in 2021, focuses on healthcare products and brands, accessing advanced technologies in microbiology and pharmaceuticals. It expects over EUR 4 million in revenues for 2024, forecasting a 35% increase to EUR 5.5 million in 2025, with a positive operating result. The long-term target is an annual revenue growth of 25% and an operating margin between 15% and 20% by 2029.

The acquisition is anticipated to be completed by January 1, 2025, pending due diligence. The purchase price of up to EUR 2 million will be paid through new shares in Viromed, utilizing the Authorized Capital 2022.